Sanofi Exercises License Extension Option to Nurix’s STAT6 Program
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Leerink Partners Reiterates Market Perform Rating on Nurix (NRIX)
June 2, 2025 11:14 AM EDTLeerink Partners analyst Faisal Khurshid reiterated a Market Perform rating and $16.00 price target on Nurix (NASDAQ: NRIX).
The analyst comments "Bottom Line: This morning NRIX announced that partner SAN FP (OP, Risinger) exercised their option to license NRIX's STAT6 program, including development candidate NX-3911. We believe NRIX's STAT6 program has been seen as an interesting... More



